Pages that link to "Q44484456"
Jump to navigation
Jump to search
The following pages link to NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma (Q44484456):
Displaying 92 items.
- HDACs and the senescent phenotype of WI-38 cells (Q24810847) (← links)
- Clinical use and applications of histone deacetylase inhibitors in multiple myeloma (Q26745930) (← links)
- Panobinostat for the treatment of multiple myeloma: the evidence to date (Q26778674) (← links)
- Novel agents for multiple myeloma to overcome resistance in phase III clinical trials (Q26822754) (← links)
- Bioactive heterocycles containing endocyclic N-hydroxy groups (Q27025241) (← links)
- Novel therapeutic strategies for multiple myeloma (Q28081590) (← links)
- From bench to bedside: lessons learned in translating preclinical studies in cancer drug development (Q28533949) (← links)
- Anticancer activities of histone deacetylase inhibitors (Q29616624) (← links)
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma (Q33410997) (← links)
- Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma (Q33854012) (← links)
- Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. (Q34194704) (← links)
- New insights into the treatment of multiple myeloma with histone deacetylase inhibitors (Q34224278) (← links)
- Histone modification enzymes: novel targets for cancer drugs (Q34322087) (← links)
- The DAC system and associations with multiple myeloma. (Q34414447) (← links)
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma (Q34441748) (← links)
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. (Q34488424) (← links)
- Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer (Q34528291) (← links)
- The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma (Q34602263) (← links)
- HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma (Q34707183) (← links)
- New insights, recent advances, and current challenges in the biological treatment of multiple myeloma (Q34773850) (← links)
- The role of DNA synthesis imaging in cancer in the era of targeted therapeutics (Q34907192) (← links)
- Augmenting antitumor immune responses with epigenetic modifying agents (Q35048054) (← links)
- Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype (Q35595410) (← links)
- Histone deacetylase inhibitors in clinical development (Q35609717) (← links)
- Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress (Q35750893) (← links)
- Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma (Q35764582) (← links)
- The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy (Q36087855) (← links)
- Targeted therapy in multiple myeloma (Q36108614) (← links)
- Targeting signalling pathways for the treatment of multiple myeloma (Q36150866) (← links)
- Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach (Q36177918) (← links)
- Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? (Q36179533) (← links)
- Histone deacetylase inhibitors: insights into mechanisms of lethality (Q36219726) (← links)
- Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates (Q36372894) (← links)
- Advances in oral therapy for multiple myeloma. (Q36436240) (← links)
- Targeting epigenetic abnormalities with histone deacetylase inhibitors (Q36529933) (← links)
- Lenalidomide in multiple myeloma (Q36573818) (← links)
- Investigational treatments for multiple myeloma (Q36654336) (← links)
- The evolving role of lenalidomide in the treatment of hematologic malignancies (Q36739807) (← links)
- Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (Q36889961) (← links)
- The aggresome pathway as a target for therapy in hematologic malignancies (Q36984494) (← links)
- Preclinical studies of novel targeted therapies (Q36998210) (← links)
- From the bench to the bedside: emerging new treatments in multiple myeloma (Q37028598) (← links)
- Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. (Q37083880) (← links)
- Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications (Q37201984) (← links)
- Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies (Q37226511) (← links)
- Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors (Q37284812) (← links)
- Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors (Q37326878) (← links)
- Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma (Q37379984) (← links)
- Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. (Q37426386) (← links)
- Targeted therapies in multiple myeloma (Q37431609) (← links)
- Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib (Q37457302) (← links)
- Novel therapeutic targets for multiple myeloma (Q37707383) (← links)
- Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma (Q37954600) (← links)
- Panobinostat for the treatment of multiple myeloma (Q37992104) (← links)
- Understanding the molecular biology of myeloma and its therapeutic implications (Q38065305) (← links)
- Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies (Q38159805) (← links)
- Epigenetic modulating agents as a new therapeutic approach in multiple myeloma (Q38161731) (← links)
- Transcript, methylation and molecular docking analyses of the effects of HDAC inhibitors, SAHA and Dacinostat, on SMN2 expression in fibroblasts of SMA patients (Q38767134) (← links)
- Histone deacetylase inhibitors in multiple myeloma: from bench to bedside (Q38813504) (← links)
- Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death (Q38906685) (← links)
- Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. (Q38950582) (← links)
- The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway (Q39113061) (← links)
- Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model (Q39174431) (← links)
- Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics (Q39234159) (← links)
- A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). (Q39248784) (← links)
- A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. (Q39403830) (← links)
- Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways (Q39523561) (← links)
- The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells (Q39658232) (← links)
- HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells (Q39706886) (← links)
- The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells (Q40105829) (← links)
- Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma (Q40341141) (← links)
- Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma (Q40396320) (← links)
- Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo (Q40501526) (← links)
- Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma (Q40520464) (← links)
- Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance (Q41203569) (← links)
- SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors (Q41487113) (← links)
- Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells (Q42156460) (← links)
- The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide (Q44913883) (← links)
- Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma (Q46192240) (← links)
- A new therapy with bortezomib, an oncologic medicinal product of the year 2004 (Q46873208) (← links)
- Modulation of antitumor immunity with histone deacetylase inhibitors. (Q49557954) (← links)
- DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. (Q52676395) (← links)
- The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. (Q53391458) (← links)
- Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. (Q53447100) (← links)
- The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. (Q54539131) (← links)
- Histone deacetylase inhibitors in cancer therapy (Q57272462) (← links)
- The biological significance of histone modifiers in multiple myeloma: clinical applications (Q58718492) (← links)
- Emerging therapies for multiple myeloma (Q83402616) (← links)
- Histone deacetylase inhibitors in the treatment for multiple myeloma (Q86335209) (← links)
- A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma (Q91586791) (← links)
- Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner (Q91756067) (← links)
- Histone deacetylase inhibitors in multiple myeloma (Q93541719) (← links)